Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0H2DL
|
|||
| Drug Name |
PMID26560530-Compound-50
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
University of Texas
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H16N6O3S
|
|||
| Canonical SMILES |
CC(=O)NC1=CC(=CC=C1)N2N=C(N=N2)SCC(=O)C3=CC(=NO3)C4=CC=CC=C4
|
|||
| InChI |
1S/C20H16N6O3S/c1-13(27)21-15-8-5-9-16(10-15)26-23-20(22-25-26)30-12-18(28)19-11-17(24-29-19)14-6-3-2-4-7-14/h2-11H,12H2,1H3,(H,21,27)
|
|||
| InChIKey |
ZSSIYCOJZBCFEO-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Tissue transglutaminase (TG2) | Target Info | Inhibitor | [1] |
| Target's Patent Info | Tissue transglutaminase (TG2) | Target's Patent Info | [1] | |
| KEGG Pathway | Huntington's disease | |||
| Pathway Interaction Database | Beta1 integrin cell surface interactions | |||
| Thromboxane A2 receptor signaling | ||||
| Alpha9 beta1 integrin signaling events | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.